Gilead's ad campaign aims to underscore that Yeztugo — its next-generation shot to stop HIV infection — is taken just twice a ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) submissions for ...

Add Yahoo as a preferred source to see more of our stories on Google. Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for ...

HIV/AIDS activists heralded the approval of a new twice-yearly pre-exposure prophylaxis (PrEP) medication last year, but these celebrations were tempered by insurers’ reluctance to cover its ...

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV ...

Gilead pharmaceutical company announced today (Tuesday, Feb. 18) that the U.S. Food and Drug Administration has accepted the company’s “new drug applications” for lencapavir, a twice-yearly injectable ...

Add Yahoo as a preferred source to see more of our stories on Google. The Food and Drug Administration has approved a highly effective new HIV-prevention medication, Gilead Sciences reported Wednesday ...

HIV advocates are concerned that upcoming changes to Gilead Sciences Inc.'s Advancing Access program mean that there will be less money available to local providers for related virus prevention.

In the 1980s, ACT UP demanded action from the U.S. government and got results with drama. AIDS activists today have fresh tactics for their new... AIDS Activists Take Aim At Gilead To Lower Price Of ...

Gilead Sciences announced last week it will donate millions of free bottles of Truvada for PrEP to the Centers for Disease Control and Prevention, but many AIDS activists say it is not enough. In a ...

Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...

– Gilead Also Recently Submitted Applications for Lenacapavir for PrEP to the European Medicines Agency That Will Be Reviewed Under Accelerated Assessment Review Timeline – FOSTER CITY, ...